🔗 Share this article

Given that the US proceeds with historic adjustments to its vaccine guidelines, a particular individual has emerged in a surprising turn: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who rose to prominence by questioning COVID-19 vaccinations throughout the global health crisis and has concentrated on potential fatalities following COVID-19 immunization in her recent time at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Vaccine Schedule

Agency leaders were set to reveal sweeping revisions to the pediatric vaccine schedule recently, bringing the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US at odds with many the international standard with no evidence for public health gain. The announcement has been postponed until the new year.

Instead of Vinay Prasad, Dr. Høeg is listed to address the audience at the event. She was recently named acting director of the FDA’s drug evaluation center, the fifth appointee to lead the office this calendar year.

A New Direction at the Agency

The acting appointment could signify a closer partnership between the drug and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a increased emphasis upon reevaluating already-approved vaccines at the FDA.

The new acting director has repeatedly called for halting certain pediatric vaccine recommendations in the US so as to align more like Denmark, a nation with nationalized medicine and a citizenry approximately the size of the state of Wisconsin.

So far comments, she has persisted in emphasizing on vaccines – typically the domain of Dr. Prasad, head of the FDA’s vaccine center – instead of pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been standard for previous directors of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for running the CDER, remarked Dr. Jonathan Howard. “She has not conducted a clinical trial. She lacks experience in running a sizeable institution. She is not an expert in drug approvals.”

Previous heads of the center would “be deeply familiar with regulatory frameworks and the science of medication creation”, commented Janet Woodcock. “Frankly, she has not acquired the kind of background that previous people who headed CBER have had.”

CDER has an immense portfolio at the agency, Woodcock emphasized.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There is also a biosimilars program, OTC medication office and other areas, and all of those have to be supervised,” she explained. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Additionally, a major management element to the position, which manages over 5,000 staff members. “It’s a huge management job, if you execute it properly,” she said.

Response and Controversial Initiatives

In response to inquiries about Dr. Høeg's fitness for the role and whether this appointment represents greater collaboration among agency officials on immunizations, a press secretary responded that the “concerns stem from flawed presumptions”.

“Her experience matches the functions of her role,” the spokesperson stated, noting the time Dr. Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computational safety modeling and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new fast-track approval initiative, a controversial one-day drug-approval program that apparently worried her preceding directors. “By what process are these medications being picked for this voucher program? Who takes the choices?” Howard asked. “There is a lot of confidentiality happening at the FDA right now.”

Overall, he remarked, “the agency seems to be moving towards laxer oversight of pharmaceuticals, except for immunizations.”

Public Past Work on Vaccines

With immunizations, Høeg has a clearer, if troubling, track record, Howard have noted. She released a analysis using non-validated public submissions to assess the frequency of myocarditis after Covid immunization. She counseled the state of Florida top health official Dr. Joseph Ladapo, who reportedly have modified findings to imply COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the new administration included altering guidelines for recently developed shots and discontinuing “optional” immunizations, she said after the election on a podcast. At the FDA, Dr. Høeg has reportedly proposed barring teenage boys from getting Covid vaccinations.

“She is an thorough ideologue who starts off with her conclusions and reverse-engineers to retrofit the science in a extremely disingenuous, dishonest way,” Howard said.

Taking Control and a “Push for Payback”

Høeg aligned with fellow dissenters, {like|